IONS IONIS PHARMACEUTICALS INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 874015 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-0.7%
TTM net income YoY-113.2%
TTM EPS YoY-96.4%
Revenue 3-yr CAGR16.0%
Net income 3-yr CAGR—
Margins
Gross margin98.2%
Operating margin-58.8%
Net margin-56.9%
FCF margin-64.2%
EBITDA margin-57.4%
Returns
ROE-108.1%
ROA-18.4%
ROIC (approx.)-236.8%
Asset turnover0.32x
Leverage & solvency
Liabilities / assets86.5%
Debt / equity0.00x
Current ratio5.43x
Interest coverage-29.37x
Cash quality & payout
Operating cash flow / net income1.00x
Accruals ratio-0.1%
Payout ratio—
Capex / revenue7.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $943.71M | $705.14M | $787.65M | $587.37M | $810.46M |
| Cost of revenue | $15.91M | $11.21M | $9.13M | $14.12M | $10.84M |
| Gross profit | $927.80M | $693.92M | $778.51M | $573.25M | $799.61M |
| R&D expense | $915.62M | $901.53M | $899.62M | — | $638.20M |
| SG&A expense | $393.87M | $267.47M | $232.62M | $150.29M | $186.35M |
| Operating income | -$381.68M | -$475.08M | -$353.73M | -$410.19M | -$30.19M |
| Interest expense | $17.26M | $16.99M | $12.66M | $8.12M | $9.35M |
| Pretax income | -$379.60M | -$460.07M | -$333.96M | -$257.99M | -$29.15M |
| Income tax | $1.79M | -$6.17M | $32.32M | $11.74M | -$551,000 |
| Net income | -$381.39M | -$453.90M | -$366.29M | -$269.72M | -$28.60M |
| EBITDA | -$371.68M | -$465.47M | -$343.44M | -$395.86M | -$14.70M |
| EPS (basic) | -2.38 | -3.04 | -2.56 | -1.90 | -0.20 |
| EPS (diluted) | -2.38 | -3.04 | -2.56 | -1.90 | -0.20 |
| Weighted avg. shares (diluted) | 160.01M | 149.51M | 143.19M | 141.85M | 141.02M |
| Balance sheet | |||||
| Cash & equivalents | $372.26M | $242.08M | $399.27M | $276.47M | $869.19M |
| Short-term investments | $2.31B | $2.06B | $1.93B | $1.71B | $1.25B |
| Inventory | $10.05M | $12.51M | $7.44M | $22.03M | $24.81M |
| Current assets | $2.99B | $2.62B | $2.64B | $2.20B | $2.35B |
| PP&E, net | $123.05M | $94.25M | $71.04M | $74.29M | $178.07M |
| Intangibles | — | — | — | — | $29.00M |
| Total assets | $3.52B | $3.00B | $2.99B | $2.53B | $2.61B |
| Current liabilities | $781.57M | $309.32M | $448.09M | $311.56M | $240.55M |
| Short-term debt | $432.12M | $165,000 | $157,000 | $151,000 | — |
| Long-term debt | $1.33B | $1.20B | $1.24B | $1.18B | — |
| Total debt | $1.76B | $1.20B | $1.24B | $1.18B | — |
| Total liabilities | $3.03B | $2.42B | $2.60B | $1.96B | $1.84B |
| Shareholders' equity | $489.09M | $588.35M | $386.69M | $572.89M | $771.74M |
| Net debt | $1.39B | $960.49M | $841.89M | $899.40M | — |
| Shares outstanding | 163.30M | 157.91M | 144.34M | 142.06M | 141.21M |
| Cash flow statement | |||||
| Operating cash flow | -$268.58M | -$500.95M | -$307.51M | -$274.37M | $30.80M |
| Capital expenditure | $51.44M | $45.28M | $23.80M | $15.72M | $11.96M |
| Free cash flow | -$320.03M | -$546.23M | -$331.32M | -$290.09M | $18.84M |
| Investing cash flow | -$277.78M | -$134.03M | -$214.13M | -$262.64M | $194.91M |
| Financing cash flow | $675.84M | $478.06M | $644.08M | -$55.30M | $245.93M |
| Depreciation & amortization | $10.01M | $9.61M | $10.29M | $14.33M | $15.49M |
| Stock-based compensation | $133.87M | $130.20M | $105.81M | $100.26M | $120.68M |
| Share buybacks | — | — | — | $0 | $0 |
Free plan shows the latest 5 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.